Traditional Chinese medicine composition and application thereof in prevention or treatment of obesity

By modifying the Wendan Decoction and adding traditional Chinese medicine ingredients such as Scutellaria baicalensis, stir-fried hawthorn, raw coix seed, and leech, the problems of adverse reactions and low acceptance of chemical drug treatment for obesity have been solved, achieving safe and effective treatment of obesity and improvement of metabolic diseases.

CN121668276APending Publication Date: 2026-03-17TONGLIAO HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610174698.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-02-06
Publication Date
2026-03-17

AI Technical Summary

Technical Problem

Existing chemical drugs for treating obesity have many adverse reactions and low patient acceptance, while traditional Chinese medicine lacks precision and comprehensive regulatory effects in the treatment of obesity.

Method used

Combining modern obesity pathology, we have innovatively modified Wendan Decoction by adding ingredients such as Scutellaria baicalensis, stir-fried hawthorn, raw coix seed, and leech to form a traditional Chinese medicine composition. Through methods of clearing heat and drying dampness, resolving phlegm and removing blood stasis, and strengthening the spleen and unblocking the meridians, it is prepared into decoctions, granules, pills, or tablets for the treatment of obesity and related metabolic diseases.

Benefits of technology

It significantly reduces body weight, visceral fat, serum cholesterol and triglycerides, increases high-density lipoprotein cholesterol, and improves hepatic steatosis. The overall clinical efficacy rate is 94.4%, with high safety and high patient acceptance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121668276A_ABST
    Figure CN121668276A_ABST
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition and application thereof in prevention or treatment of obesity, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from rhizoma pinellinae praeparata, caulis bambusae in taeniam, fructus aurantii immaturus, pericarpium citri reticulatae, poria cocos, radix scutellariae, fried hawthorn fruits, raw coix seeds, leeches, fresh ginger, Chinese dates and raw licorice roots according to specific weight parts. On the basis of a classic famous prescription, namely gallbladder-warming decoction, according to the traditional Chinese medicine pathology of qi loss of three jiao and damp heat-phlegm stasis-collateral obstruction, medicines such as scutellaria baicalensis, fried hawthorn, raw semen coicis, leech and the like are added, so that the fat-reducing gallbladder-warming decoction is formed. The composition has the effects of eliminating dampness and phlegm, clearing heat and eliminating blood stasis, and tonifying spleen and dredging collaterals. Animal experiments show that the traditional Chinese medicine composition can significantly reduce the weight, body fat and blood fat of obese mice and improve fatty degeneration of livers; clinical research shows that the weight, BMI, waistline, blood fat and traditional Chinese medicine syndromes of obese patients can be effectively improved, the total effective rate reaches 94.4%, and safety is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine composition technology, specifically to a traditional Chinese medicine composition and its application in the prevention or treatment of obesity. Background Technology

[0002] Due to changes in modern lifestyles and dietary patterns, the global obesity rate is rising year by year. Data from the World Health Organization (WHO) shows that the number of overweight or obese people worldwide increased from 929 million in 1990 to 2.6 billion in 2021. Obesity not only increases the risk and burden of cardiovascular disease, metabolic syndrome, and certain cancers, but also...

[0003] Obesity is a complex chronic metabolic disease characterized by excessive fat accumulation in the body. It is measured by body mass index (BMI), with a BMI ≥ 30 defined as obesity. Its pathogenesis is not only characterized by increased body weight but also closely related to abnormal fat accumulation, metabolic disorders, and endocrine imbalances. Currently, chemical drugs used clinically to treat obesity include orlistat. These drugs primarily reduce body weight by decreasing fat absorption and suppressing appetite. However, long-term use can easily lead to adverse gastrointestinal and cardiovascular reactions. Furthermore, patients often find it psychologically difficult to accept taking chemical drugs to control their weight.

[0004] Traditional Chinese medicine (TCM) has a long history of treating obesity, possessing advantages such as safety, stable efficacy, and holistic regulation. TCM categorizes obesity into terms like "fat person," "greasy person," and "spleen deficiency," believing its core pathogenesis lies in the dysfunction of the internal organs, leading to the accumulation of dampness, phlegm, and fat within the body. Treatment emphasizes "syndrome differentiation and treatment" and "comprehensive conditioning" to restore organ function and improve metabolic imbalances. TCM compound formulas can exert a comprehensive regulatory effect through multiple components, targets, and pathways, exhibiting characteristics of holistic conditioning, minimal adverse reactions, and high acceptability. Therefore, the application of TCM compound formulas in the treatment of obesity has received widespread attention.

[0005] Wendan Decoction is a classic Chinese medicine formula for resolving phlegm and harmonizing the stomach. Based on inheriting and developing the theories of damp-heat diseases from Ming and Qing dynasty febrile disease scholars and Ye Tianshi's "dispersing and eliminating method," and combined with the epidemiological characteristics and clinical practice of contemporary obese patients, the inventor proposed a pathological evolution pathway of obesity centered on "disorders of the three jiaos' qi transformation, damp-heat-phlegm-stasis-collateral obstruction." Guided by this theory, Wendan Decoction was modified and innovated to more precisely treat obesity with damp-heat as the core pathogenesis, thus developing the Chinese herbal composition described in this invention. Summary of the Invention

[0006] The present invention aims to provide a traditional Chinese medicine composition that has good efficacy and high safety in treating obesity, in order to solve the problems of many adverse reactions and low patient acceptance of existing chemical drugs, and to provide an effective traditional Chinese medicine solution for the prevention and treatment of obesity.

[0007] In the first aspect, to achieve the above objectives, the present invention adopts the following technical solution: a traditional Chinese medicine composition, made from the following raw materials in parts by weight: 5-15 parts of processed Pinellia ternata, 5-15 parts of bamboo shavings, 5-15 parts of immature bitter orange, 5-15 parts of dried tangerine peel, 10-20 parts of Poria cocos, 5-15 parts of Scutellaria baicalensis, 10-20 parts of stir-fried hawthorn, 10-20 parts of raw Coix lacryma-jobi, 1-3 parts of leech, 3-5 slices of ginger, 1-2 jujubes, and 5-15 parts of raw licorice.

[0008] Preferably, as an improvement, the dosage of each raw material is as follows: 10 parts of Pinellia ternata, 10 parts of bamboo shavings, 10 parts of Citrus aurantium, 15 parts of Citrus reticulata peel, 7.5 parts of Poria cocos, 10 parts of Scutellaria baicalensis, 15 parts of stir-fried hawthorn, 15 parts of raw Coix lacryma-jobi, 3 parts of leech, 5 slices of ginger, 1 jujube, and 10 parts of raw licorice.

[0009] Preferably, as an improvement, the dosage form of the traditional Chinese medicine composition is a decoction, granules, pills, capsules, or tablets.

[0010] Secondly, the application of the aforementioned traditional Chinese medicine composition in the preparation of drugs for treating or improving obesity and related metabolic diseases.

[0011] The obesity and related metabolic diseases include simple obesity, spleen deficiency and dampness obstruction type obesity, hyperlipidemia or non-alcoholic fatty liver disease.

[0012] The effects of the drug include reducing weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio, serum total cholesterol, triglycerides, low-density lipoprotein cholesterol, and / or increasing high-density lipoprotein cholesterol.

[0013] This invention's drug combination originates from the classic formula "Wen Dan Tang". Targeting the core pathogenesis of obesity—damp-heat, phlegm-stasis, and meridian obstruction—it creatively adds the following ingredients to the Wen Dan Tang formula (containing Pinellia ternata, bamboo shavings, immature bitter orange, tangerine peel, Poria cocos, ginger, jujube, and licorice) to regulate qi, resolve phlegm, harmonize the stomach, and promote bile secretion: Scutellaria baicalensis: Clears heat and dries dampness, drains fire and detoxifies, targeting damp-heat pathogens.

[0014] Stir-fried hawthorn: It aids digestion, strengthens the stomach, promotes blood circulation, removes blood stasis, clears turbidity, and lowers lipids, thereby eliminating fat and improving blood flow.

[0015] Raw Job's tears: promotes diuresis and eliminates dampness, strengthens the spleen and clears heat, thus removing dampness and turbidity and strengthening the middle jiao (spleen and stomach).

[0016] Leeches: They break up blood stasis and unblock the meridians, and are effective against blood stasis caused by prolonged illness.

[0017] The formula embodies the principles of "dispersing and eliminating" and "treating both qi and blood." Based on years of clinical experience, the drug described in this invention has been expanded and innovated, showing good efficacy in improving obesity and metabolic diseases. The principal ingredient is Pinellia ternata, which is pungent and warm, dries dampness, resolves phlegm, harmonizes the stomach, and stops vomiting. Bamboo shavings are used as assistant ingredients, chosen for their sweet and slightly cold properties to clear heat, resolve phlegm, relieve stagnation, and stop vomiting. Leeches break up accumulations, remove blood stasis, and unblock the meridians. Together, they remove phlegm and blood stasis in the qi level, restoring the function of qi transformation, resolving phlegm and blood stasis to lower lipids. The combination of Pinellia ternata and bamboo shavings, one warm and one cool, effectively resolves phlegm, harmonizes the stomach, stops vomiting, and relieves irritability. Bamboo shavings and leeches together resolve phlegm and unblock the meridians, helping to remove deep-seated turbidity from the blood vessels and reduce lipids. Hawthorn promotes digestion, strengthens the stomach, invigorates blood, removes blood stasis, and lowers lipids. Coix seed promotes diuresis, eliminates dampness, strengthens the spleen, stops diarrhea, clears heat, and removes turbidity. The combination of hawthorn and coix seed synergistically enhances the effects of "removing dampness, resolving stagnation, and regulating the spleen," thus addressing the root cause of obesity. Tangerine peel is bitter, pungent, and warm, regulating qi, relieving stagnation, drying dampness, and resolving phlegm; immature bitter orange is bitter, pungent, and slightly cold, lowering qi, promoting circulation, eliminating phlegm, and removing lumps. The combination of tangerine peel and immature bitter orange, one warm and one cool, amplifies their effects of regulating qi, resolving phlegm, and lowering lipids. Poria cocos is added to strengthen the spleen, replenish qi, dry dampness, and promote urination. The combination of tangerine peel and poria cocos eliminates the source of phlegm and dampness. Ginger and jujubes are added to the decoction to harmonize the spleen and stomach, and licorice root is used as an adjuvant to harmonize the effects of all the herbs.

[0018] When used together, these herbs achieve the effects of clearing heat and drying dampness, resolving phlegm and removing blood stasis, strengthening the spleen and unblocking the meridians, and reducing fat and weight. They can promote weight loss in obese patients, improve blood lipids, protect the liver, and regulate metabolic disorders.

[0019] The beneficial effects of this invention are: 1. Based on classic prescriptions, modifications are made according to the innovative pathological theory of obesity, namely "damp-heat-phlegm-stasis-collateral obstruction," resulting in a more precise correspondence between prescription and syndrome.

[0020] 2. Effective treatment Animal experiments have shown that this drug composition can significantly reduce body weight, visceral fat weight and body fat percentage in obese mice induced by a high-fat diet; effectively reduce serum total cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), and increase high-density lipoprotein cholesterol (HDL-C); and significantly improve hepatic steatosis (reduction of lipid droplet vacuoles).

[0021] A clinical study investigated the treatment results of 90 obese patients with spleen deficiency and dampness obstruction, showing a total effective rate of 94.4%. After treatment, patients' body weight (BW), body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR), and blood lipid indicators (TC, TG, LDL-C, HDL-C) were all significantly improved compared with those before treatment (P<0.05), and their TCM syndrome scores also decreased significantly.

[0022] 3. High safety: All medicinal materials used in the formula are listed in the pharmacopoeia, and no obvious adverse reactions have been observed in clinical applications, resulting in high patient acceptance.

[0023] 4. Wide range of applications: It can be used not only to treat simple obesity, but also to comprehensively improve accompanying metabolic disorders such as hyperlipidemia and non-alcoholic fatty liver disease. Attached Figure Description

[0024] Figure 1 Effects of the drug on mouse body weight, visceral fat, and body fat percentage; Note: Compared with the normal group, **P<0.01; compared with the model group, ##P<0.01; compared with drug 1 group, &&P<0.01; Figure 2 Serum lipid levels in each group of mice; Note: Compared with the normal group, **P<0.01; compared with the model group, ##P<0.01; compared with drug 1 group, &&P<0.01; Figure 3 HE pathological staining results of the livers of mice in each group; Figure 4 HE oil red staining results of mouse livers in each group; Figure 5 Serum lipid levels in each group of mice; Figure 6 : Results of liver appearance in mice of each group. Detailed Implementation

[0025] The following detailed description illustrates the specific implementation method: A traditional Chinese medicine composition for treating obesity includes 5-15g of prepared Pinellia ternata, 5-15g of bamboo shavings, 5-15g of immature bitter orange, 5-15g of dried tangerine peel, 10-20g of Poria cocos, 5-15g of Scutellaria baicalensis, 10-20g of stir-fried hawthorn, 10-20g of raw coix seed, 1-3g of leech, 3-5 slices of ginger (approximately 9-15g), 1-2 jujubes (approximately 10g, broken open for easier extraction of active ingredients), and 5-15g of raw licorice root. In traditional Chinese medicine, the dosage of each drug is adjusted according to the patient's individual condition. In this invention, adjusting the dosage of each drug within the appropriate range ensures safety and effectiveness.

[0026] Example 1 (Drug 1): Clinically proven to have a very good effect on improving obesity, and combined with the clinical experience of traditional Chinese medicine, the following compound formula has better efficacy: Pinellia ternata 10g, Bambusa textilis 10g, Citrus aurantium 10g, Citrus reticulata 15g, Poria cocos 7.5g, Scutellaria baicalensis 10g, Crataegus pinnatifida 15g, Coix lacryma-jobi 15g, Hirudo medicinalis 3g, fresh ginger 5 slices, jujube 1 piece, and licorice root 10g.

[0027] Example 2: Preparation of Xiaozhi Wendan Decoction. The traditional Chinese medicine composition of Example 1 was prepared into a decoction according to the following method.

[0028] Weigh out the Chinese herbal medicine composition according to the specified amount and place it in a container. Add 6 times the volume (1200mL) of distilled water and soak for 40 minutes. Transfer the soaked herbs and soaking liquid to a heating pot and heat to boiling for 40 minutes. Filter the liquid into a container for temporary storage. Transfer the filtered residue to the heating pot, add 6 times the volume of distilled water, heat to boiling for 40 minutes, and then filter. A total of 3 filtered liquids are obtained. Combine the liquids and concentrate to obtain Xiaozhi Wendan Decoction.

[0029] Animal experiments—to investigate the effects of any combination of the innovative components in the traditional Chinese medicine composition of this invention for treating obesity: Scutellaria baicalensis, Coix lacryma-jobi, stir-fried hawthorn, and leech (only a portion of the many exploratory experiments).

[0030] (I) Experimental Design and Methods 1. Establishment of a mouse obesity model and grouping for drug administration After 3 weeks of stable rearing, mice weighing 20–22 g were randomly divided into a normal control group (n=8) and a high-fat diet group (n=48). After 8 weeks of feeding with a high-fat diet, 48 successfully modeled obese mice were selected based on a body weight ≥ 1.2 times that of the normal control group and randomly assigned to the following groups: Model group Drug 1 (Example 1): Wendan Decoction + Scutellaria baicalensis 10g, stir-fried hawthorn 15g, raw coix seed 15g, leech 3g; Medication 2: Wendan Decoction + Scutellaria baicalensis 10g + raw Coix seed 15g + stir-fried hawthorn 15g; Medication 3: Wendan Decoction + Scutellaria baicalensis 10g + raw Coix seed 15g + leech 3g; Medication 4: Wendan Decoction + 15g raw coix seed + 15g stir-fried hawthorn + 3g leech; Medication 5: Wendan Decoction + Scutellaria baicalensis 10g + raw Coix seed 15g + stir-fried hawthorn 15g + Panax notoginseng 3g; Drug 6: Wendan Decoction (classic original formula): Pinellia ternata 10g, Bamboo shavings 10g, Fructus Aurantii Immaturus 10g, Pericarpium Citri Reticulatae 15g, Poria cocos 7.5g, Ginger 5 slices, Jujube 1 piece, Licorice 10g.

[0031] Each drug group was prepared into a decoction using the method described in Example 2, according to the drug dosage in Example 1. Eight mice were used in each group. The drug dosage for mice was calculated based on the conversion between human and mouse body surface area. The mice were administered the drugs by gavage for four consecutive weeks. During this period, both the model group and the drug groups were continuously fed a high-fat diet.

[0032] 2. Sample Collection and Processing: Serum Lipid Level Detection After administration, the mice were fasted overnight, and blood was collected from the orbital cavity and preserved. The mice were euthanized by cervical dislocation, and the inguinal and epididymal fats were quickly dissected and separated, and weighed. A portion of the fat was cut and fixed in 4% paraformaldehyde fixative, and the remaining adipose tissue was flash-frozen in liquid nitrogen and stored at -80°C for later use.

[0033] 3. Serum lipid level test: Whole blood was centrifuged at 4°C and 3000 r / min for 10 min. The supernatant serum was collected, and serum TC, TG, HDL, and LDL levels were measured according to the kit instructions.

[0034] 4. Hematoxylin-eosin (HE) staining: Liver tissue fixed in 4% paraformaldehyde fixative was taken, and a suitable size was placed in a tissue embedding cassette. The tissue was slowly dehydrated in a tissue dehydrator, embedded in paraffin, and tissue sections of about 5 μm were cut. After baking for 30 min, the sections were dewaxed and hydrated, stained with hematoxylin and eosin, dehydrated and mounted. The cell morphology of fat was observed and photographed under a microscope, and the histological images were quantitatively analyzed using ImageJ software.

[0035] 5. Oil Red O staining Prepare the Oil Red O staining working solution (Oil Red O solution: Oil Red O diluent = 3:2). Take out the frozen sections stored at -20℃ and place them on the slide rack to thaw for 10 min. Add an appropriate amount of staining and washing solution to cover the sample for 20 seconds. Remove the staining and washing solution, and add the prepared Oil Red O staining working solution to the sections for staining for 20 min. Remove the Oil Red O staining working solution, add an appropriate amount of staining and washing solution to the sections, let stand for 30 seconds, then remove the staining and washing solution, and immerse in distilled water for 20 seconds. Stain with hematoxylin staining solution for 1 min, and then wash with distilled water for 30 seconds. Mount the sections with an anti-fluorescence quencher.

[0036] (II) Experimental Results 1. Effects of the drug on mouse body weight, visceral fat, and body fat percentage As the feeding time of mice increased, the body weight of mice in each group changed to varying degrees, while the amount of drug intake in each group did not show significant differences over time; the results of visceral fat weight and body fat percentage in each group showed that, compared with the control group, the body weight, visceral fat weight, and body fat percentage of the model group were all increased. P <0.01); Compared with the model group, the body weight, visceral fat weight and fat body ratio of each drug group (except drug 6) decreased to varying degrees. P <0.01, P <0.05), the order of drug efficacy is drug 1, drug 5, drug 3, drug 4, drug 2. See Figure 1 .

[0037] 2. Effects of the drug on serum lipid levels in mice Serum lipid profiles in mice across all groups showed that, compared to the control group, serum TG, TC, and LDL-C levels in the model group were significantly elevated. Compared to the model group, serum TG, TC, and LDL-C levels in all drug-treated groups (except drug 6) decreased to varying degrees, while HDL-C levels significantly increased. The order of drug efficacy was drug 1, drug 5, drug 3, drug 4, and drug 2. (See attached data). Figure 2 .

[0038] 3. Effects of the drug on mouse liver pathology Histopathological observation of liver tissue revealed that the blank group showed intact liver lobule structure and radially arranged hepatocytes; while the model group and drug group 6 showed hepatocyte swelling and lipid droplet vacuolation. Other drug groups showed a significant reduction in lipid droplet vacuolation area and improved hepatic cord structure. Figure 3 .

[0039] 4. Effects of the drug on oil red staining of mouse liver Oil Red O staining analysis of mouse liver tissue revealed fewer red lipid droplets in the liver tissue of the control group, which were sporadically distributed within the liver cells. In contrast, the liver tissue sections of the model group and the drug 6 group showed significant lipid deposition, with red lipid droplets occupying most of the cytoplasmic area. Compared to the model group, the red lipid droplets in the liver tissue of mice in all drug-treated groups (except drug 6) were significantly reduced, and lipid deposition was improved, showing a certain dose-dependent effect. Figure 4 .

[0040] In summary, compared with the results of other drug groups, drug 1 (Wen Dan Tang + Scutellaria baicalensis + Coix seed + stir-fried hawthorn + leech) was the best in reducing weight, body fat, blood lipids and improving hepatic steatosis. This indicates that the addition of Scutellaria baicalensis, Coix seed, stir-fried hawthorn and leech has a synergistic effect with Wen Dan Tang, and together they constitute the core prescription for the pathogenesis of obesity of "damp-heat-phlegm-stasis-collateral obstruction".

[0041] Animal experiments – to investigate the efficacy of the traditional Chinese medicine composition of the present invention for the treatment of obesity.

[0042] (I) Experimental Design and Methods 1. Establishment of a mouse obesity model and grouping for drug administration After 3 weeks of stable feeding, mice weighing 20–22 g were randomly divided into a normal control group (n=8) and a high-fat diet group (n=48). After 8 weeks of feeding the high-fat diet group, 40 successfully modeled obese mice were selected based on a body weight ≥ 1.2 times that of the normal control group. These mice were then randomly divided into a model group, a low-dose Xiaozhi Wendan Decoction group, a medium-dose Xiaozhi Wendan Decoction group, a high-dose Xiaozhi Wendan Decoction group, and an orlistat group (n=8 in each group). The dosage for mice was calculated using the human-to-mouse body surface area conversion method, and different doses of Xiaozhi Wendan Decoction solution were administered to the mice. The orlistat group received orlistat aqueous solution (90 mg / kg) via gavage for 4 consecutive weeks. During this period, the model group, Xiaozhi Wendan Decoction group, and orlistat group continued to be fed a high-fat diet.

[0043] 2. Sample Collection and Processing: Serum Lipid Level Detection After administration, the mice were fasted overnight, and blood was collected from the orbital cavity and preserved. The mice were euthanized by cervical dislocation, and the inguinal and epididymal fats were quickly dissected and separated, and weighed. A portion of the fat was cut and fixed in 4% paraformaldehyde fixative, and the remaining adipose tissue was flash-frozen in liquid nitrogen and stored at -80°C for later use.

[0044] 3. Serum lipid level test: Whole blood was centrifuged at 4°C and 3000 r / min for 10 min. The supernatant serum was collected, and serum TC, TG, HDL, and LDL levels were measured according to the kit instructions.

[0045] 4. Hematoxylin-eosin (HE) staining: Liver tissue fixed in 4% paraformaldehyde fixative was taken, and a suitable size was placed in a tissue embedding cassette. The tissue was slowly dehydrated in a tissue dehydrator, embedded in paraffin, and tissue sections of about 5 μm were cut. After baking for 30 min, the sections were dewaxed and hydrated, stained with hematoxylin and eosin, dehydrated and mounted. The cell morphology of fat was observed and photographed under a microscope, and the histological images were quantitatively analyzed using ImageJ software.

[0046] 5. Oil Red O staining Prepare the Oil Red O staining working solution (Oil Red O solution: Oil Red O diluent = 3:2). Take out the frozen sections stored at -20℃ and place them on the slide rack to thaw for 10 min. Add an appropriate amount of staining and washing solution to cover the sample for 20 seconds. Remove the staining and washing solution, and add the prepared Oil Red O staining working solution to the sections for staining for 20 min. Remove the Oil Red O staining working solution, add an appropriate amount of staining and washing solution to the sections, let stand for 30 seconds, then remove the staining and washing solution, and immerse in distilled water for 20 seconds. Stain with hematoxylin staining solution for 1 min, and then wash with distilled water for 30 seconds. Mount the sections with an anti-fluorescence quencher.

[0047] 5. Immunofluorescence staining Tissue sections were dewaxed and washed with PBST, then incubated with 5% bovine serum albumin in a 37°C water bath for 1 hour. Subsequently, they were incubated overnight at 4°C with primary anti-PPARG antibody (1:50), followed by incubation at 37°C for 1 hour. FITC-labeled goat anti-rabbit IgG (1:1000) was then incubated at 37°C for 30 minutes. Finally, the nuclei were stained with DAPI for 10 minutes, followed by counterstaining with hematoxylin. Relative expression levels were observed and quantitatively analyzed using a fluorescence microscope.

[0048] (I) Experimental Results 1. Effects of Xiaozhi Wendan Decoction on body weight, visceral fat, and body fat percentage in mice As the feeding time of mice increased, the body weight of mice in each group changed to varying degrees. Except for the orlistat group, the food intake of mice decreased, and the food intake of the other groups did not change significantly over time. The results of visceral fat weight and body fat percentage of mice in each group showed that, compared with the control group, the body weight, visceral fat weight and body fat percentage of the model group were all increased. P <0.01; Compared with the model group, the body weight, visceral fat weight and fat body ratio of the Xiaozhi Wendan Decoction group all decreased to varying degrees. P <0.01, P <0.05), and showed a dose-dependent effect. See Table 1.

[0049] Table 1. Effects of Xiaozhi Wendan Decoction on body weight, visceral fat, and body fat percentage in mice.

[0050] Note: b) Compared with the normal group, P<0.01; c) Compared with the model group, P<0.05; d) Compared with the model group, P<0.01.

[0051] 2. Effects of Xiaozhi Wendan Decoction on serum lipid levels in mice Serum lipid profiles in mice from each group showed that, compared with the control group, serum TG, TC, and LDL-C levels in the model group were significantly increased (P<0.05). Compared with the model group, serum TG, TC, and LDL-C levels in mice treated with medium and high doses of Xiaozhi Wendan Decoction decreased to varying degrees (P<0.05), while HDL-C levels significantly increased (P<0.05), showing a certain dose-dependent effect. Figure 5 .

[0052] 3. Effects of Xiaozhi Wendan Decoction on Liver Pathology in Mice Liver morphological analysis showed that the livers in the control group exhibited a typical bright red appearance and moderate volume. The model group and the low-dose Xiaozhi Wendan Decoction group showed significant hepatomegaly and characteristic pale white changes, suggesting abnormal lipid accumulation. Compared with the model group, the livers in the medium-dose and high-dose Xiaozhi Wendan Decoction groups showed restored liver color and reduced volume compared to the model group. Figure 6 .

[0053] IV. Clinical Case Analysis 1. General information: Ninety patients with simple obesity treated in outpatient and inpatient departments were included in the study. Among them, 40 patients were aged 18-35 years, 30 patients were aged 35-50 years, and 20 patients were over 50 years old.

[0054] 2. Diagnostic criteria: Western medicine diagnostic criteria: Referring to the "Diagnostic and Efficacy Evaluation Criteria for Simple Obesity" and the "Chinese Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)" and considering the characteristics of the regional population, the diagnostic criteria are as follows: (1) Actual body weight > 20% or more of the standard body weight; (2) Waist circumference > 85cm for men and > 80cm for women; (3) BMI > 26 or more; A diagnosis can be made if two of the above three criteria are met and secondary obesity is excluded. Note: ① Formula for calculating standard weight for adults: (height (cm) - 100) × 0.9 = standard weight (kg); ② Formula for calculating body mass index (BMI): BMI = weight (kg) / height (m) 2 .

[0055] Traditional Chinese Medicine (TCM) Diagnostic Criteria: TCM classification refers to the Spleen Deficiency and Dampness Retention type in the "Chinese Guidelines for the Diagnosis and Treatment of Obesity (2024 Edition)". Symptoms include: obesity, heaviness in the limbs, lethargy, poor appetite, abdominal distension, scanty urine, pale red tongue with a white, greasy coating, and a slow pulse. If three or more of the above symptoms are present, and the tongue and pulse characteristics are generally consistent, the patient can be diagnosed with Spleen Deficiency and Dampness Retention type obesity.

[0056] 3. Inclusion criteria: Only those who meet all of the following conditions can be included: (1) meet the Western medicine diagnostic criteria for obesity; (2) meet the TCM syndrome differentiation of spleen deficiency and dampness obstruction type obesity; (3) age range: 18 years old < patient < 65 years old, male or female; (4) have not received obesity-related drug treatment in the past month; (5) have stable vital signs, clear consciousness, and no serious underlying diseases; (6) agree to participate in the observation, voluntarily become a subject, and be able to accept the observation and treatment and guarantee to complete the course of treatment.

[0057] 4. Exclusion criteria: Patients who do not meet any of the following criteria will not be included: (1) Those who do not meet the TCM syndrome criteria for obesity and the inclusion criteria for cases; (2) Patients with serious primary diseases or serious complications; (3) Patients who have taken hormone drugs in the past 3 months; (4) Patients with severe malnutrition, poor general condition, and inability to cooperate with examination and treatment; (5) Patients who are known to be allergic to the ingredients of this drug or to multiple drugs; (6) Patients whose case data is incomplete and affects the judgment; (7) Patients who are unwilling to cooperate with treatment, do not take the drug as prescribed, thus affecting the efficacy, as well as pregnant or lactating women; 5. Treatment methods: A single-arm trial was conducted to develop a standardized obesity treatment plan.

[0058] 5.1. Conventional treatment: (1) Obesity health education; (2) Reasonable diet plan; (3) Appropriate exercise and quitting bad habits such as smoking and drinking; (4) Treatment of other underlying diseases of patients does not interfere with this study.

[0059] 5.2. Drug treatment: The Xiaozhi Wendan Decoction obtained in Example 2 was taken warm 30 minutes after breakfast and dinner. Follow-up visits were conducted once every 1-2 weeks, with a treatment cycle of 2 months. Treatment was based on the patient's four diagnostic methods, and the specific dosage of the drugs was adjusted reasonably within the above dosage range.

[0060] 6. Observation items: (1) General information: including the patient's gender, age, height and other basic information; (2) Obesity-related indicators: weight (BW), body mass index (BMI), waist circumference (WC), hip circumference (HC), waist-to-hip ratio (WHR, the ratio of waist circumference to hip circumference); (3) Clinical efficacy indicators: referring to the "Diagnosis and Efficacy Evaluation Criteria for Simple Obesity", cured: weight within the normal range or overweight, waist circumference reduced by 10cm; significantly effective: body mass index decreased by ≥4, waist circumference reduced by 8-10cm; effective: body mass index decreased by ≥2 but <4, waist circumference reduced by 2-8cm; ineffective: no change in weight or body mass index decreased by <2, waist circumference not reduced or reduced by <2cm. (4) Traditional Chinese Medicine syndrome scoring scale: calculated according to the standard scale of traditional Chinese medicine syndrome scoring.

[0061] 7. Observation Results Table 2. Clinical efficacy assessment before and after treatment in obese patients

[0062] Table 3. Comparison of obesity-related indicators before and after treatment in obese patients

[0063] The differences in BW, BMI, WC, HC, and WHR before and after treatment between the two groups of patients were statistically significant. # P <0.05 Table 4. Comparison of blood lipid levels before and after treatment in obese patients

[0064] The differences in TC, TG, LDL-C, and HDL-C between the two groups of patients before and after treatment were statistically significant. # P <0.05 Table 5. Comparison of TCM syndrome scores before and after treatment in obese patients

[0065] Δ represents the difference between the initial syndrome score and the final TCM syndrome score; compared with the scores before and after treatment in this group, # P<0.05.

[0066] Clinical studies have shown that Xiaozhi Wendan Decoction combined with diet, exercise, and lifestyle intervention can effectively improve the body weight (BW), body mass index (BMI), blood volume (WC), blood glucose (HC), blood heart rate (WHR), blood lipid levels, and TCM syndrome scores of obese patients before and after treatment. Furthermore, it has demonstrated good safety during clinical treatment, with no adverse reactions.

[0067] The above descriptions are merely embodiments of the present invention, and common knowledge such as specific technical solutions and / or characteristics are not described in detail here. It should be noted that those skilled in the art can make various modifications and improvements without departing from the technical solutions of the present invention, and these should also be considered within the scope of protection of the present invention. These modifications and improvements will not affect the effectiveness of the implementation of the present invention or the practicality of the patent. The scope of protection claimed in this application should be determined by the content of its claims, and the specific embodiments described in the specification can be used to interpret the content of the claims.

Claims

1. A traditional Chinese medicine composition, characterized in that, Mainly by the following weight parts of raw materials: Banxia 5~15 parts, Zhuzu 5~15 parts, Cishu 5~15 parts, Chenpi 5~15 parts, Fuling 10~20 parts, Huangqi 5~15 parts, Chaoshanzha 10~20 parts, Shengyiren 10~20 parts, Shuiji 1~3 parts, Shengjiang 3~5 pieces, Dazao 1~2 pieces, Shenggancao 5~15 parts.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The dosage of each raw material is: Banxia 10 parts, Zhuzu 10 parts, Cishu 10 parts, Chenpi 15 parts, Fuling 7.5 parts, Huangqi 10 parts, Chaoshanzha 15 parts, Shengyiren 15 parts, Shuiji 3 parts, Shengjiang 5 pieces, Dazao 1 piece, Shenggancao 10 parts.

3. The traditional Chinese medicine composition according to claim 1 or 2, characterized in that, The dosage form of the traditional Chinese medicine composition is decoction, granules, pills, capsules or tablets.

4. The use of the traditional Chinese medicine composition of claim 1 or 2 in the preparation of a medicament for treating or / and preventing or / and improving obesity and related metabolic diseases.

5. Use according to claim 4, characterized in that, The obesity and related metabolic diseases include simple obesity, spleen deficiency and dampness obstruction type obesity, hyperlipidemia or non-alcoholic fatty liver.

6. Use according to claim 4, characterized in that, The efficacy of the medicament includes reducing body weight, body mass index, waist circumference, hip circumference, waist-hip ratio, serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, and / or increasing high-density lipoprotein cholesterol. The efficacy of the medicament includes reducing body weight, body mass index, waist circumference, hip circumference, waist-hip ratio, serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, and / or increasing high-density lipoprotein cholesterol.